Efficacy of Necitumumab

Necitumumab can be combined with Gemcitabine and Cisplatin chemotherapy after approval by the U.S. Food and Drug Administration (FDA) Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this disease. However, nexituzumab is not suitable for treating non-squamous non-small cell lung cancer.

In a study of epidermal growth factor receptor inhibitors in squamous non-small cell lung cancer, baseline characteristics and chemotherapy exposure were well balanced in the nesituzumab-continuation arm and the gemcitabine-cisplatin non-progression arm, as well as in the EGFR-expressing population. After randomization, the median overall survival (OS) of the gemcitabine-cisplatin group and the gemcitabine-cisplatin non-progression group were 15.9 and 15.0 months, respectively, and the median progression-free survival (PFS) of the randomized group were 7.4 and 6.9 months, respectively. OS and PFS benefits were similar when assessed from post-induction phase and EGFR-expressing patients. Therefore, compared with the gemcitabine-cisplatin non-progression group, the sustained treatment effect of nexituzumab was consistent, with no unexpected increase in adverse reactions in the intention-to-treat and EGFR-expressing populations.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.